PYC Therapeutics Ltd
ASX:PYC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
PYC Therapeutics Ltd
Total Assets
PYC Therapeutics Ltd
Total Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
PYC Therapeutics Ltd
ASX:PYC
|
Total Assets
AU$159.1m
|
CAGR 3-Years
71%
|
CAGR 5-Years
20%
|
CAGR 10-Years
32%
|
|
|
Mesoblast Ltd
ASX:MSB
|
Total Assets
$782.3m
|
CAGR 3-Years
5%
|
CAGR 5-Years
3%
|
CAGR 10-Years
0%
|
|
|
CSL Ltd
ASX:CSL
|
Total Assets
$37.9B
|
CAGR 3-Years
2%
|
CAGR 5-Years
16%
|
CAGR 10-Years
18%
|
|
|
Race Oncology Ltd
ASX:RAC
|
Total Assets
AU$24.8m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
21%
|
CAGR 10-Years
N/A
|
|
|
Clinuvel Pharmaceuticals Ltd
ASX:CUV
|
Total Assets
AU$269.7m
|
CAGR 3-Years
19%
|
CAGR 5-Years
25%
|
CAGR 10-Years
37%
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Total Assets
AU$1.2B
|
CAGR 3-Years
66%
|
CAGR 5-Years
49%
|
CAGR 10-Years
N/A
|
|
PYC Therapeutics Ltd
Glance View
PYC Therapeutics Ltd. is a drug-development company, which offers a new generation of RNA therapeutics to meet unmet need in disease. The company is headquartered in Nedlands, Western Australia. The company went IPO on 2005-03-30. The firm has RNA targeted therapeutics design capabilities to deliver technology based on cell penetrating peptides (CPPs). The firm develops a pipeline of therapies, including three preclinical stage programs, which are focused on inherited eye diseases and preclinical discovery efforts, which are focused on neurodegenerative diseases. The Company’s lead drug candidate, VP-001 is designed to treat Retinitis pigmentosa 11 (RP11). The second lead drug candidate VP-002, which is focused on treating autosomal dominant optic atrophy (ADOA) and PYC-001 drug candidate to treat diabetic retinopathy. Its preclinical, clinical, regulatory and corporate operations are based in San Diego, California. The firm's discovery and laboratory operations are located in Australia.
See Also
What is PYC Therapeutics Ltd's Total Assets?
Total Assets
159.1m
AUD
Based on the financial report for Dec 31, 2025, PYC Therapeutics Ltd's Total Assets amounts to 159.1m AUD.
What is PYC Therapeutics Ltd's Total Assets growth rate?
Total Assets CAGR 10Y
32%
Over the last year, the Total Assets growth was 133%. The average annual Total Assets growth rates for PYC Therapeutics Ltd have been 71% over the past three years , 20% over the past five years , and 32% over the past ten years .
